News Column

BrainStorm Gets United States Patent Office Notice of Allowance for Its Stem Cell Technology

January 16, 2014

BrainStorm Cell Therapeutics, a developer of adult stem cell technologies for neurodegenerative diseases, announced that it has received a Notice of Allowance from the U.S. Patent Office for its "Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases" (serial number 11/727,583) patent application.

According to a release, this patent relates to the method of production of the company's proprietary stem cells induced to secrete large quantities of neurotrophic factors for the treatment of neurodegenerative diseases. Pending approval from the FDA, the company is currently preparing for its upcoming multi-center Phase II trial in the U.S. with its proprietary NurOwn stem cell therapy, which was developed from this method.

"This U.S. patent allowance solidifies our intellectual property protection for our unique production method, as it reinforces the Notice recently received from the European Patent Office for the same technology, announced last week," commented Chaim Lebovits, BrainStorm's President and Principal Executive Officer.

BrainStorm noted it is the exclusive worldwide licensee of this technology from Ramot, the technology transfer company of Tel Aviv University, where it was developed by Professors Daniel Offen and Eldad Melamed.

BrainStorm Cell Therapeutics Inc. is a biotechnology company.

More Information:

((Comments on this story may be sent to

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Professional Services Close - Up

Story Tools